I hope shareholders (current and prospective) realize the importance of partnering with such a huge pharma company and the implications for what it could, possibly, mean down the road to Bioasis!

https://jnjinnovation.com/about-us#par-8761
Mission

Johnson & Johnson Innovation seeks to positively impact human health through innovation. We do this by helping entrepreneurs realize their dreams of creating healthcare solutions that improve people's lives around the world. We work side-by-side with innovators throughout their journey, providing a robust exchange of ideas and resources to support their success. 

Our mission is to create the leading global innovation network to generate transformational healthcare solutions through value-creating partnerships.

 
https://jnjinnovation.com/partnering/pharmaceuticals
Focus Areas
Our Pharmaceuticals business is divided into six core areas, Cardiovascular & Metabolism; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension. We seek innovation across all of these areas where there is significant unmet patient need.
We are also pioneering Data Science and digital healthcare and reimagining how we Discover, Develop & Supply transformational medicines to patients around the world.

Collaboration Partners
Johnson & Johnson Innovation is comprised of a family of complementary teams that bring meaningful solutions and flexible approaches to support collaboration. From incubation facilities to early-stage investing – from venture funding to acquisition, our teams offer partners a full range of capabilities. 

https://jnjinnovation.com/janssenbusinessdevelopment

Janssen Business Development
Identifying Pathways to Better Health Through Collaboration
About Us

Johnson & Johnson Innovation | Janssen Business Development seeks to identify collaborative opportunities that will create transformative value for our partners and the world.

Driving Collaborative Innovation to Accelerate Breakthroughs

The Janssen Business Development team focuses on mid- and late-stage collaborations with established pharmaceutical and biotechnology companies to accelerate breakthrough innovation to solve unmet medical needs and create real value in Janssen’s six defined therapeutic areas. We are very active in acquiring assets, companies, and technologies as well as entering into strategic collaborations, licenses, profit splits, and commercial partnerships.

The Janssen Business Development team has a proven, positive track record of deal performance. We are focused on genuine collaborations and take a thoughtful approach to risk-taking. No two deals are exactly alike, and we spend the time to understand the unique needs of our partners and optimize deal structures tailored to maximize value for all parties.

Our goal is to form active partnerships where we can bring the full strength of Johnson & Johnson to bear to create a lasting and valuable relationship. Our direct access to decision makers within Johnson & Johnson allows for creative and timely problem solving, and we integrate deal makers with science leaders from the very beginning to optimize success.

If you represent the appropriate type of company, seek a collaboration or merger and acquisition discussions, or have a compound that has shown proof of concept in humans, make the connection with Johnson & Johnson Innovation, Janssen Business Development.

Focus Areas
Our Pharmaceuticals business is focused in six core therapeutic areas, Cardiovascular & Metabolism; Immunology; Infectious Diseases & Vaccines; Neuroscience (includes Neurodegenerative Disorders); Oncology; and Pulmonary Hypertension. In addition, we have teams dedicated to Diagnostics & Enabling Technologies; Global Public Health; Emerging Markets; and Divestitures & Out-licensing. Janssen Business Development seeks opportunities across all of these areas where there is strong science and significant unmet patient need.

https://www.janssen.com/neuroscience/neurodegeneration

We are in the midst of a scientific renaissance in neurodegeneration, driven by growing evidence of overarching biological processes that drive neurodegenerative disorders.
Our ambition at Janssen is to become a leader in neurodegeneration. We are working to develop innovations for a diverse range of patients, from large, clinically diverse populations to rare diseases within which genetic markers may further development of therapies for other idiopathic diseases.
This work begins with R&D, where we have potentially transformational early science in Alzheimer’s disease (AD) and Parkinson’s disease. For example, in AD, we are utilizing plasma biomarkers in our trials to detect central amyloid positivity and tau status.
The recent launch of our disease modifying therapy in multiple sclerosis was also a critical step toward our re-entry into neurology and, most importantly, offers patients a meaningful choice for treatment backed by nearly a decade of research.